TORONTO--(BUSINESS WIRE)--Aug 18, 2025--

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (" Cybin " or the " Company "), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the " Meeting "). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below: